Molecular link between diabetes and schizophrenia connects food and mood

Jun 08, 2010

Defects in insulin function - which occur in diabetes and obesity - could directly contribute to psychiatric disorders like schizophrenia.

Vanderbilt University Medical Center investigators have discovered a molecular link between impaired insulin signaling in the brain and schizophrenia-like behaviors in mice. The findings, reported June 8 in PLoS Biology, offer a new perspective on the psychiatric and cognitive disorders that affect patients with diabetes and suggest new strategies for treating these conditions.

"We know that people with diabetes have an increased incidence of mood and other ," said endocrinologist Kevin Niswender, M.D., Ph.D. "And we think that those co-morbidities might explain why some patients have trouble taking care of their diabetes."

"Something goes wrong in the brain because insulin isn't signaling the way that it normally does," said neurobiologist Aurelio Galli, Ph.D.

Galli's group was among the first to show that insulin - the hormone that governs in the body - also regulates the brain's supply of dopamine - a neurotransmitter with roles in motor activity, attention and reward. Disrupted dopamine signaling has been implicated in including depression, Parkinson's disease, schizophrenia and .

Now, Galli, Niswender, and colleagues have pieced together the molecular pathway between perturbed insulin signaling in the brain and dopamine dysfunction leading to schizophrenia-like behaviors.

The researchers developed mice with an insulin-signaling defect only in neurons (they impaired the function of the protein Akt, which transmits insulin's signal inside cells). They found that the mice have behavioral abnormalities similar to those frequently seen in patients with schizophrenia.

They also showed how defects in insulin signaling disrupt neurotransmitter levels in the brain - the mice have reduced dopamine and elevated norepinephrine in the prefrontal cortex, an important area for cognitive processes. These changes resulted from elevated levels of the transporter protein (NET) that removes norepinephrine and dopamine from the synaptic space between neurons.

"We believe the excess NET is sucking away all of the dopamine and converting it to norepinephrine, creating this situation of hypodopaminergia (low levels of dopamine) in the cortex," Galli explained. Low dopamine function in the cortex is thought to contribute to the cognitive deficits and negative symptoms - depression, social withdrawal - associated with schizophrenia.

By treating the mice with NET inhibitors (drugs that block NET activity), the investigators were able to restore normal cortical dopamine levels and behaviors. Clinical trials of NET inhibitors in patients with schizophrenia are already under way, Galli said, and these new data provide mechanistic support for this approach.

The findings also provide a molecular basis for interpreting previous reports of Akt deficiencies in patients with schizophrenia, as revealed by post-mortem, imaging and genetic association studies.

Galli and Niswender suggest that the insulin to Akt signaling pathway is critical for "fine-tuning" the function of monoamine neurotransmitters - dopamine, and serotonin - and that it can be impaired in many different ways.

"Dysregulation of this pathway - because of type 1 diabetes, because of a high-fat diet, because of drugs of abuse, because of genetic variations - may put a person on the road to neuropsychiatric disorders," Galli said.

Understanding the molecular link between insulin action and balance - the connection between food and mood - offers the potential for novel therapeutic approaches, the researchers said. The mouse model described in the current studies may be useful for testing schizophrenia and cognition-enhancing treatments.

Explore further: The impact of bacteria in our guts

More information: Siuta MA, Robertson SD, Kocalis H, Saunders C, Gresch PJ, et al. (2010) Dysregulation of the Norepinephrine Transporter Sustains Cortical Hypodopaminergia and Schizophrenia-Like Behaviors in Neuronal Rictor Null Mice. PLoS Biol 8(6): e1000393. doi:10.1371/journal.pbio.1000393

Related Stories

Protein on 'speed' linked to ADHD

Jul 08, 2008

A genetic change in the dopamine transporter – one of the brain's dopamine-handling proteins – makes it behave as if amphetamine is present and "run backward," Vanderbilt University Medical Center investigators report ...

Researchers find 'switch' for brain's pleasure pathway

Mar 22, 2006

Amid reports that a drug used to treat Parkinson's disease has caused some patients to become addicted to gambling and sex, University of Pittsburgh researchers have published a study that sheds light on what may have gone ...

New dopamine brain target discovered

Jan 23, 2007

A team of Canadian researchers, lead by Dr. Susan George and Dr. Brian O'Dowd at the Centre for Addiction and Mental health (CAMH), discovered a distinct dopamine signalling complex in the brain. Composed of two different ...

Cocaine's effects on brain metabolism may contribute to abuse

Feb 18, 2008

Many studies on cocaine addiction - and attempts to block its addictiveness - have focused on dopamine transporters, proteins that reabsorb the brain's "reward" chemical once its signal is sent. Since cocaine blocks dopamine ...

Recommended for you

The impact of bacteria in our guts

Aug 22, 2014

The word metabolism gets tossed around a lot, but it means much more than whether you can go back to the buffet for seconds without worrying about your waistline. In fact, metabolism is the set of biochemical ...

Stem cell therapies hold promise, but obstacles remain

Aug 22, 2014

(Medical Xpress)—In an article appearing online today in the journal Science, a group of researchers, including University of Rochester neurologist Steve Goldman, M.D., Ph.D., review the potential and ch ...

New hope in fight against muscular dystrophy

Aug 22, 2014

Research at Stockholm's KTH Royal Institute of Technology offers hope to those who suffer from Duchenne muscular dystrophy, an incurable, debilitating disease that cuts young lives short.

Biologists reprogram skin cells to mimic rare disease

Aug 21, 2014

Johns Hopkins stem cell biologists have found a way to reprogram a patient's skin cells into cells that mimic and display many biological features of a rare genetic disorder called familial dysautonomia. ...

User comments : 0